Treatment-emergent adverse events affecting ≥15% of subjects treated with BG00010 (any dose) or ≥15% of subjects treated with placebo.i.v., intravenous; N/A, not applicable; s.c., subcutaneous.Treatme
Treatment-emergent adverse events affecting ≥15% of subjects treated with BG00010 (any dose) or ≥15% of subjects treated with placebo. i.v., intravenous; N/A, not applicable; s.c., subcutaneous. Treat
Objective Previous evidence has established that micronutrient capsules can improve emotion regulation in children. This three-phased randomized open-label waitlist-controlled study investigated the s
ObjectivePrevious evidence has established that micronutrient capsules can improve emotion regulation in children. This three-phased randomized open-label waitlist-controlled study investigated the sa